The central role of monocytes in the pathogenesis of sepsis: Consequences for immunomonitoring and treatment

Netherlands Journal of Medicine

Volumn 55, Issue 3, 1999, Pages 132-141

  Haveman, J W ^a   Muller Kobold, A C ^a   Cohen Tervaert, J W ^a   Van Den Berg, A P ^a   Tulleken, J E ^a   Kallenberg, C G M ^a   The, T H ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

CARS; Cytokines; Immunoparalysis; Monocyte activation; Prognosis; Sepsis; SIRS

Indexed keywords

ANTIINFECTIVE AGENT; CYTOKINE; GAMMA INTERFERON; HLA DR ANTIGEN; IMMUNOSTIMULATING AGENT; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 8; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; PROSTAGLANDIN E2; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; CYTOKINE RELEASE; HUMAN; IMMUNE SYSTEM; INFLAMMATION; MONOCYTE; MORTALITY; PATHOGENESIS; PROGNOSIS; REVIEW; SEPSIS;

EID: 0032795046     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-2977(98)00156-9     Document Type: Article

References (45)

1. Bone RC, Grodzin CJ, Balk RA. Sepsis: a new hypothesis for pathogenesis of the disease process. Chest 1997;112:235-43.
2. Ulevitch RJ, Tobias PS. Receptor-dependent mechanisms of cell stimulation by bacterial endotoxin. Annu Rev Immunol 1995;13:437-57.
3. Malhotra R, Bird MI. L-selectin: a novel receptor for lipopolysaccharide and its potential role in bacterial sepsis. Bioessays 1997;19:919-23.
4. Weiss SJ. Tissue destruction by neutrophils. N Engl J Med 1989;320:365-76.
5. Davies MG, Hagen PO. Systemic inflammatory response syndrome. Br J Surg 1997;84:920-35.
6. Bone RC. Immunologic dissonance: a continuing evolution in our understanding of the systemic inflammatory response syndrome (SIRS) and the multiple organ dysfunction syndrome (MODS). Ann Intern Med 1996;125:680-7.
7. Abraham E, Anzueto A, Gutierrez G et al. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. Lancet 1998;351:929-33.
8. Cohen J, Carlet J. INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. Crit Care Med 1996;24:1431-40.
9. Fisher Jr. CJ, Agosti JM, Opal SM et al. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. N Engl J Med 1996;334:1697-702.
10. Fisher Jr. CJ, Slotman GJ, Opal SM et al. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. Crit Care Med 1994;22:12-21.
11. Dhainaut JF, Tenaillon A, Le TY, Schlemmer B et al. Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: a randomized, double-blind, placebo-controlled, multicenter clinical trial. Crit Care Med 1994;22:1720-8.
12. The Veterans Administration Systemic Sepsis Cooperative Study Group. Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. N Engl J Med 1987;317:659-65
13. Cohen J, Heumann D, Glauser MP. Do monoclonal antibodies and anticytokines still have a future in infectious diseases? Am J Med 1995;99:45S-52S.
14. Avontuur JA, Tutein NR, van BJ, Bruining HA. Prolonged inhibition of nitric oxide synthesis in severe septic shock: a clinical study. Crit Care Med 1998;26:660-7.
15. Bone RC. Sir Isaac Newton, sepsis. SIRS, and CARS Crit Care Med 1996;24:1125-8.
16. Hershman MJ, Cheadle WG, Wellhausen SR, Davidson PF, Polk Jr. HC. Monocyte HLA-DR antigen expression characterizes clinical outcome in the trauma patient. Br J Surg 1990;77:204-7.
17. Gibbons RA, Martinez OM, Lim RC, Horn JK, Garovoy MR. Reduction in HLA-DR, HLA-DQ and HLA-DP expression by Leu-M3 + cells from the peripheral blood of patients with thermal injury. Clin Exp Immunol 1989;75:371-5.
18. Wakefield CH, Carey PD, Foulds S, Monson JR, Guillou PJ. Changes in major histocompatibility complex class II expression in monocytes and T cells of patients developing infection after surgery. Br J Surg 1993;80:205-9.
19. Cheadle WG, Hershman MJ, Wellhausen SR, Polk Jr. HC. HLA-DR antigen expression on peripheral blood monocytes correlates with surgical infection. Am J Surg 1991;161:639-45.
20. Asadullah K, Woiciechowsky C, Döcke WD et al. Very low monocytic HLA-DR expression indicates high risk of infection- immunomonitoring for patients after neurosurgery and patients during high dose steroid therapy. Eur J Emerg Med 1995;2:184-90.
21. van den Berk JMM, Oldenburger RH, van den Berg AP et al. Low HLA-DR expression on monocytes as a prognostic marker for bacterial sepsis after liver transplantation. Transplantation 1997;63:1846-8.
22. Hummel M, Döcke WD, Friedel N, von Baehr R, Hetzer R, Volk HD. Monitoring of the cellular immune system in patients with biventricular assist devices awaiting cardiac transplantation. Clin Transplant 1994;8:59-66.
23. Volk HD, Reinke P, Krausch D et al. Monocyte deactivation-rationale for a new therapeutic strategy in sepsis. Intensive Care Med 1996;22(Suppl 4):S474-81.
24. Volk HD, Reinke P, Falck P, Briedigkeit H, von Baehr R. Diagnostic value of an immune monitoring program for the clinical management of immunosuppressed patients with septic complications. Clin Transplant 1989;3:246-52.
25. Döcke WD, Syrbe U, Meinecke A et al. Improvement in monocyte function - a new therapeutic approach. In: Reinhart K, Eyerich K, Sprung C, editors, Sepsis: Update in Intensive Care and Emergency Medicine, New York: Springer Verlag, 1994, p. 473.
26. de Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991;174:1209-20.
27. Randow F, Syrbe U, Meisel C et al. Mechanism of endotoxin desensitization: involvement of interleukin 10 and transforming growth factor beta. J Exp Med 1995;181:1887-92.
28. Astiz M, Saha D, Lustbader D, Lin R, Rackow E. Monocyte response to bacterial toxins, expression of cell surface receptors, and release of anti-inflammatory cytokines during sepsis. J Lab Clin Med 1996;128:594-600.
29. Klava A, Windsor AC, Farmery SM et al. Interleukin-10. A role in the development of postoperative immunosuppression. Arch Surg 1997;132:425-9.
30. Sherry RM, Cue JI, Goddard JK, Parramore JB, DiPiro JT. Interleukin-10 is associated with the development of sepsis in trauma patients. J Trauma 1996;40:613-6.
31. Haupt W, Fritzsche H, Hohenberger W, Zirngibl H. Selective cytokine release induced by serum and separated plasma from septic patients. Eur J Surg 1996;162:769-76.
32. Capsoni F, Minonzio F, Ongari AM, Carbonelli V, Galli A, Zanussi C. Interleukin-10 down-regulates oxidative metabolism and antibody-dependent cellular cytotoxicity of human neutrophils. Scand J Immunol 1997;45:269-75.
33. Bogdan C, Vodovotz Y, Nathan C. Macrophage deactivation by interleukin 10. J Exp Med 1991;174:1549-55.
34. de Waal Malefyt R, Haanen J, Spits H et al. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med 1991;174:915-24.
35. Muller Kobold AC, Tulleken JE, Zijlstra JG, Cohen Tervaert JW. Interleukin 10 in febrile patients and patients with sepsis [letter]. Lancet 1998;351:1587.
36. Armendariz BJ, Endres RO, Ballou LR, Postlethwaite AE. Transforming growth factor-beta inhibits interferon-gamma-induced HLA-DR expression by cultured human fibroblasts. Int J Biochem Cell Biol 1996;28:1107-16.
37. Snyder DS, Beller DI, Unanue ER. Prostaglandins modulate macrophage Ia expression. Nature 1982;299:163-5.
38. Watanabe Y, Lee S, Allison AC. Control of the expression of a class II major histocompatibility gene (HLA-DR) in various human cell types: down-regulation by IL-1 but not by IL-6, prostaglandin E2, or glucocorticoids. Scand J Immunol 1990;32:601-9.
39. Kunkel SL, Campbell Jr. DA, Chensue SW, Higashi GI. Species-dependent regulation of monocyte/macrophage Ia antigen expression and antigen presentation by prostaglandin E. Cell Immunol 1986;97:140-5.
40. Randow F, Döcke WD, Bundschuh DS, Hartung T, Wendel A, Volk HD. In vitro prevention and reversal of lipopolysaccharide desensitization by IFN-gamma, IL-12, and granulocyte-macrophage colony-stimulating factor. J Immunol 1997;158:2911-8.
41. Döcke WD, Randow F, Syrbe U et al. Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat Med 1997;3:678-81.
42. Chantry D, Turner M, Brennan F, Kingsbury A, Feldmann M. Granulocyte-macrophage colony stimulating factor induces both HLA-DR expression and cytokine production by human monocytes. Cytokine 1990;2:60-7.
43. Vincent JL. Search for effective immunomodulating strategies against sepsis (commentary). Lancet 1998;351:922-3.
44. van Dissel JT, van Langevelde P, Westendorp RGJ, Kwappenberg K, Frolich M. Anti-inflammatory cytokine profile and mortality in febrile patients. Lancet 1998;351:950-3.
45. Kox WJ, Bone RC, Krausch D et al. Interferon gamma-1b in the treatment of compensatory anti-inflammatory response syndrome. A new approach: proof of principle. Arch Intern Med 1997;157:389-93.